Cleancard

Executive Summary

Cleancard (NumEn) is a San Francisco-based preclinical biotech-diagnostics startup dedicated to eradicating cancer deaths through rapid, at-home diagnostic tests enabled by proprietary machine-learning models. Founded in 2020, the company aims to identify cancer signatures earlier than conventional methods, thereby allowing timely therapeutic interventions. Its integrated approach combines biosensing, digital health, and AI to drive improved oncology outcomes. As a private, early-stage company with 10-50 employees, Cleancard has not yet disclosed total funding or valuation, but its focus on accessible, high-volume health data collection positions it in a competitive landscape of early cancer detection. The company is currently in the preclinical stage, with no commercial products or FDA approvals to date, indicating significant execution risk. However, its novel approach and mission-driven team suggest potential for meaningful impact if it can validate its technology and secure regulatory and commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Series A funding announcement40% success
• Q4 2026Initial preclinical validation data release50% success
• Q1 2027Strategic partnership with a major diagnostics or pharma company30% success